Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai releases lenvatinib Phase II trial preliminary results
The results from the trial showed an objective response rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine
The results from the trial showed an objective response rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine
Yellox is a non-steroidal anti-inflammatory drug (NSAID) indicated as a treatment for postoperative ocular inflammation following cataract extraction in adults. Under an agreement signed between CROMA Pharma and
Following the acquisition, Trident will become the wholly owned subsidiary of INC Research and will be operating as Trident Clinical Research, an INC Research company, through its offices
Nextrials claims Prism can be fully integrated with platforms used for electronic health records (EHR) by the healthcare industry. By receiving a constant flow of data, Prism enables
Tripos, a Certara Company, is a provider of scientific solutions, helps life science companies and research facilities accelerate the identification and optimization of new compounds. D360 is used
Prior to licensing the manufacturing facility, the Spanish Medicines Agency has conducted inspection on 15 and 16 February 2011. Midatech claims its biocompatible nanoparticles possess a number of
Aricept is the US Food and Drug Administration (FDA) approved prescription only medication for the treatment of all stages of Alzheimer’s disease – mild, moderate and severe dementia
Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3 that can influence tumor growth, vascular angiogenesis and progression of
Gliclazide is an oral anti-diabetic (hypoglycemic) drug which is classified as a sulfonylurea and is indicated for the control of hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis
Prior to joining Affymetrix, Witney worked as the president and CEO of Dionex Before joining Dionex, Witney served as executive vice president and chief commercial officer of Affymetrix,